[go: up one dir, main page]

WO1999036334A1 - Distributeur d'aerosol - Google Patents

Distributeur d'aerosol Download PDF

Info

Publication number
WO1999036334A1
WO1999036334A1 PCT/US1999/001004 US9901004W WO9936334A1 WO 1999036334 A1 WO1999036334 A1 WO 1999036334A1 US 9901004 W US9901004 W US 9901004W WO 9936334 A1 WO9936334 A1 WO 9936334A1
Authority
WO
WIPO (PCT)
Prior art keywords
valve
container
opening
annular member
aerosol
Prior art date
Application number
PCT/US1999/001004
Other languages
English (en)
Inventor
Peter D. Hodson
Original Assignee
Minnesota Mining And Manufacturing Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining And Manufacturing Company filed Critical Minnesota Mining And Manufacturing Company
Priority to EP99904119A priority Critical patent/EP1049637A1/fr
Priority to AU24588/99A priority patent/AU2458899A/en
Publication of WO1999036334A1 publication Critical patent/WO1999036334A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
    • B65D83/44—Valves specially adapted for the discharge of contents; Regulating devices
    • B65D83/52—Metering valves; Metering devices

Definitions

  • the present invention relates to dispensing devices and more particularly to improvements to metered dose inhalers which facilitate enhanced operation of metered- dose dispensing valves.
  • Formulations comprising suspensions of fine medicament particles in aerosol propellant systems are typically provided in a pressurised liquid phase within an aerosol container.
  • the liquid phase may include a mixture of chlorofluorocarbons (CFC's) or one or more hydrofluoroalkanes, such as, PI 34a (1,1,1,2-tetrafluoroethane) and P227 (1,1,1,2,3,3,3-heptafluoropropane).
  • the formulation may also contain ingredients other than medicament, such as ethanol and excipients such as surfactants; lubricants and flavouring agents may also be included.
  • the valve should sample the formulation homogeneously and uniformly in order that the correct dose of medicament is delivered to the patient on each actuation of the valve.
  • Many widely prescribed medicament substances are more dense than the liquid phase of a pressurised formulation. This is particularly true for liquid phase mixtures comprising hydrofluoroalkanes, such as PI 34a, which tend to be less dense than traditional CFC mixtures.
  • the medicament substance is more dense than the liquid phase, the medicament particles will typically settle gradually with time. This can lead to unduly high medicament concentrations within the aerosol container (e.g.
  • Typical existing inhaler metering valves include a bottle emptier or tank retaining cup which is an element that covers or partially surrounds the metering valve's dosage chamber inlet. Bottle emptiers move the effective filling point nearer to the bottom of the dispenser when the dispenser is held in the valve down position. The bottle emptier helps reduce the undeliverable volume of formulation remaining in the dispenser at the end of its life.
  • Bottle emptiers tend to restrict access of medicament formulation to the metering valve inlet which may result in loss of prime for the valve.
  • loss of prime it is meant that doses of reduced weight could be provided by the valve, particularly when the aerosol container is stored for a prolonged period of time in a valve-up orientation.
  • the loss of prime occurs when any liquid leaks or is shaken from the valve, as medicament formulation tends to be unable subsequently to completely refill the valve tank, probably due to the constricted inlet geometry, the presence of the bottle emptier or other factors.
  • PCT WO96/28367 discloses valves which have an unconstricted tank inlet geometry that allows medicament formulation to easily enter the metering volume when the valve is actuated.
  • U.S. Patent No. 4,944,433 discloses a valve for dispensing metered doses from a container comprising an element disposed about the valve housing and extending radially therefrom toward a wall of the container.
  • the element substantially closes the space between the wall of the container and the valve housing, but does provide a space adjacent the wall of the container.
  • the element has a raised peripheral portion adjacent the wall of the container.
  • containers which are left on their sides for extended periods of time may tend to accumulate sediments at the very point (the space adjacent the wall of the container) where this device affords access to the valve inlet with the attendant disadvantages associated with affording sediment access to the valve inlet. Additionally, this device may be difficult to construct as performance of the device may be particularly sensitive to manufacturing tolerances.
  • GB-2178398A, 2198117A and 2298187A disclose metering valves for metered dose inhalers comprising a valve body or housing which envelopes the metering chamber and valve stem. There is an opening, aligned with the central axis of the valve stem, to allow passage of aerosol formulation to the inlet of the metering chamber. In each case the opening in the housing is spaced from the inlet to the metering chamber, which is believed to result in an undeliverable volume of formulation remaining in the dispenser.
  • an apparatus for use with a pressurised aerosol container having a substantially cylindrical wall with a central axis, the wall defining a major storage portion of the aerosol container and an opening comprising: a ferrule for closure of said opening, a metered dose valve for dispensing a metered dose of an aerosol formulation from the container, the valve having an inlet, the valve being disposed in the ferrule substantially along the central axis, and an annular member having an inner end defining an opening that affords fluid communication between the major storage portion of the aerosol container and the inlet of the valve, the annular member being sized, shaped and positioned to restrict the fluid communication between the major storage portion of the container and the valve inlet to only that fluid communication provided through the opening of the annular member, and the opening being situated so that it is substantially adjacent the central axis.
  • the present invention provides an improvement to metered dose dispensers which effectively and efficiently dispenses medicament by improving the operation of the metering valve by reducing the chances of clogging of the metering valves by formulations, even formulations which could give rise to unduly high medicament concentrations if improperly shaken, and by reducing the access of unduly high medicament concentrations to the valve inlet in an aerosol container, even when it has been left on its side for an extended period of time.
  • the present invention includes an annular member having an inner end defining an opening that affords fluid communication between the major portion of the aerosol container and the inlet of the valve.
  • the annular member is a separate component from the valve, which facilitates manufacture since it does not add a further component to the valve assembly.
  • the annular member may be sized and shaped such that it may be retained in place when the ferrule is attached to the aerosol container.
  • the annular member is positioned to restrict the fluid communication between the major portion of the container and the valve inlet to only that fluid communication provided through the opening of the annular member.
  • the opening is situated so that it is substantially adjacent the central axis of the cylindrical wall of the container.
  • the invention has particular utility with medicaments that have particles.
  • the annular member is preferably sized, shaped and positioned to comprise a substantially oneway valve which restricts access of unduly high concentrations of medicament particles from the major portion of the container to the valve inlet but which affords passage of unduly high medicament particle concentrations near the valve inlet away from the valve inlet and toward the major portion of the aerosol container where the unduly high concentrations of medicament particles may be eliminated.
  • the annular member has a diameter along the central axis.
  • the diameter preferably decreases along the central axis in a direction away from the valve inlet.
  • the annular member of the present invention has a portion which projects toward the central axis and a portion which projects along the central axis.
  • the aerosol container has a peripheral portion adjacent the cylindrical wall of the aerosol container.
  • the annular member prevents fluid communication from the peripheral portion of the aerosol container directly to the valve inlet.
  • the annular member projects from a position at or near the wall of the container toward the central axis and prevents direct communication of unduly high concentrations of medicament in a position near the wall of the container to the valve inlet.
  • the configuration also reduces the volume of undeliverable formulation remaining in the container.
  • the opening of the annular member is situated substantially adjacent the valve inlet.
  • Figure 1 is a partial cross-sectional view of a first embodiment of improved aerosol dispensing device according to the present invention
  • Figure 2 is a partial cross-sectional view of a second embodiment of improved aerosol dispensing device according to the present invention.
  • Figure 3 is a partial cross-sectional view of a third embodiment of improved aerosol dispensing device according to the present invention.
  • the present invention provides an improvement to medicament dispensers, particularly metered dose inhalers which dispense metered amounts of aerosol medicament formulations.
  • the medicaments may be from any suitable therapeutic category such as, but not limited to antibiotics, proteins/peptides, steroids, bronchodilators, anticholinergics, lipoxygenase inhibitors, PAF antagonists, potassium channel activators, mast cell stabilisers, bradykinin analogs, enkephalins or interleukin.
  • the medicament may be leuprolide, albuterol, insulin, pirbuterol, beclomethasone, terbutaline, salmeterol, fluticasone, tiamcinolone, salbutamol, isoproterenol, epinephrine, fenoterol, formoterol, procaterol, pentamidine, calcitonin, ipratropium, oxitropium, budesonide, combinations thereof or any other composition approved for delivery to a patient.
  • This invention has particular utility with suspension based medicaments.
  • the present invention is suitable for use in metered dose dispensers which utilise formulations comprising suspensions of fine medicament particles in an aerosol propellant systems.
  • formulations typically include micronised particles having a mass median diameter of from 1 to 10 ⁇ m.
  • the formulation may comprise any formulation suitable for delivery of the aerosol medicament.
  • the liquid phase may include a mixture of chlorofluorocarbons (CFC's) or a mixture of P134a (1,1,1,2-tetrafluoroethane) and ethanol.
  • the formulation may also contain ingredients other than medicament, such as excipients. Surfactants, lubricants and flavouring agents may also be included.
  • the present invention finds particular utility for use with medicament substances that are more dense than the liquid phase of a pressurised formulation.
  • Hydrofluoroalkanes such as PI 34a
  • the medicament particles tend to settle gradually with time leading to a variety of adverse consequences.
  • a metered dose inhaler that effectively and efficiently dispenses medicament by virtue of an improved operation of the metering valve.
  • the chances of clogging of the metering valve by the formulation is substantially reduced by the improvement according to the present invention.
  • the invention comprises an apparatus for use as part of a pressurised aerosol container 15 that has a substantially cylindrical body (not shown) comprising a vial wall 1 A with a central axis, a ferrule 2 A (with substantially the same axis as that of the vial wall), and a metered dose valve 62 for dispensing aerosol formulation from the container 15.
  • the valve 62 has an inlet 4 A which allows a metered portion of the medicament formulation to enter a metering chamber. From the metering chamber, a metered amount of the medicament formulation is subsequently delivered to the patient.
  • the internal portion of the aerosol container has a major storage portion (not all of which is shown but comprising the top part of Figure 1 ) and a minor portion substantially adjacent the valve inlet 4 A.
  • the valve 62 is disposed in the ferrule 2 A substantially along the central axis of the wall 1 A or the ferrule 2 A.
  • the valve shown in Figure 1 is substantially the same as the valve shown in Figure 18 of PCT International Publication No. WO96/28367 (the entire contents of which are herein incorporated by reference).
  • the present invention can also be utilised with the other embodiments of valves shown in of PCT International Publication No. WO96/28367.
  • Figure 1 illustrates a portion of an inhaler comprising a ferrule 2 A which is crimped onto the container wall 1A.
  • the stem of the valve 62 includes an outer metal portion 64 and an elastomeric sealing element 68 comprising skirts 70, 72.
  • a stem cap 74 retains the sealing element 68 and prevents the valve stem from being pushed out of the unit by the pressure of the formulation's propellant.
  • the valve is shown in its non- dispensing position in Figure 1.
  • valve stem To meter a dose of medicament formulation, the valve stem is released and moves outward under the influence of the propellant. As the stem moves, the inner skirt 70 enters the bore of the elongated nose 86 of the valve ferrule 2A, forming a seal with the bore, and defines a metered volume of formulation in the region 58 between the skirts 70,
  • the present invention includes an annular member 90A having an inner end 78 A defining an opening 82 A that affords fluid communication between a major storage portion of the aerosol container (the top portion of Figure 1 and above) and the inlet 4 A of the valve 62.
  • the annular member 90A is sized, shaped and positioned to restrict fluid communication between the major storage portion of the aerosol container and the valve inlet 4A to only that fluid communication provided through the opening 82A of the annular member 90A.
  • the annular member 90A is also sized, shaped and positioned to comprise a substantially one-way valve which restricts access of unduly high concentrations of medicament particles from the major storage portion of the aerosol container to the valve inlet 4A but which affords passage of unduly high medicament concentrations near the valve inlet 4 A away from the valve inlet 4 A and toward the major portion of the aerosol container where the unduly high concentrations of medicament may be eliminated (e.g. by remixing).
  • the opening 82 A is preferably situated so that it is substantially adjacent the central axis of the cylindrical wall 1 A.
  • the opening 82A Placement of the opening 82 A in this fashion allows the cross sectional area of the opening 82 A to be as small as possible and provides a design that is not unduly sensitive to tolerance vagaries or assembly variances. With the opening 82A placed in the position described, it is highly unlikely that unduly high concentrations of medicament particles will be able to travel from the periphery of the wall 1 A to the inlet 4 A as the indirect or lengthy path that such particles would have to travel is likely to result in their remixture into the formulation with the attendant reduction in concentration resulting from such remixture. As illustrated in Figure 1 , the annular member 90A has a diameter that generally changes as a function of distance along the central axis.
  • the diameter decreases along the central axis in a direction away from the valve inlet (note the portion of the annular member 90A closest to the wall 1 A). That portion projects toward the central axis.
  • the annular member 90 A includes a portion which projects substantially parallel to the central axis.
  • the aerosol container has a peripheral portion adjacent the cylindrical wall 1 A.
  • the annular member 90 A prevents fluid communication from the peripheral portion of the aerosol container directly to the valve inlet 4A.
  • the present invention reduces access of unduly high medicament concentrations found near the peripheral portion (e.g. that can appear in an aerosol container which has been left on its side for a long period of time) to the valve inlet 4 A.
  • the annular member 90A projects from a position near the wall 1 A of the container toward the central axis and prevents direct communication of unduly high concentrations of medicament in a position near the wall of the container (see 84 in Figure 1) to the valve inlet 4A.
  • the annular region 84 collects the unduly high concentrations of medicament or sediment in a manner that restricts its access to the valve inlet 4A.
  • the unduly high medicament concentration must travel upward in Figure 1 from region 84, then downward through the opening 82A and into 4A. After travelling such a labyrinth like path, the unduly high medicament concentration would have had ample opportunity to mix with the rest of the formulation to thereby eliminate the medicament concentration.
  • the annular member 90A is preferably sized and shaped to ensure that there is adequate volume in the annular collecting region 84 for all of the drug-bearing sediment to collect as it first settles.
  • the opening 82A is sized and shaped to afford access for the formulation to the valve inlet 4A.
  • the opening 82A can be circular with a diameter between about 2 millimeters and about 6 millimeters, and preferably between about 4 millimeters and about 4.5 millimeters.
  • this amount of drug is equivalent to less than 10 doses, and much of this relatively small amount of additional drug will settle down in the lowest region (73) of the ferrule 2 A, away from the inlet 4A, if the unit is not shaken.
  • the present invention reduces the chances of an unduly high concentration of medicament being delivered to a patient.
  • O-ring 12A forms a gas-tight seal between the aerosol container 1 A and the ferrule 2 A.
  • a gas tight seal is not required at the juncture between the annular member
  • Figure 2 illustrates a second alternative embodiment of a device 14 according to the present invention which has many parts that are essentially the same as the parts of the device shown in Figure 1 and which have been identified by the same reference number to which the suffix "B" has been added.
  • the metered dose inhaler comprises a metering valve 14, and a ferrule 2B crimped onto the neck of container IB (e.g. a vial, the rest of which vial is not shown to emphasise other details) for the medicament formulation.
  • container IB e.g. a vial, the rest of which vial is not shown to emphasise other details
  • valve 14 To operate the valve 14, the patient presses stem 21 so that it moves further into the ferrule 2B. As the stem 21 is subsequently released and returns under the influence of spring 23, another volume of medicament formulation enters the valve via the valve inlet region 4B.
  • the valve inlet is adjacent the bottom of the inhaler when in its valve-down position due to the presence of bottle emptier 3.
  • the bottle emptier 3 is used so that nearly all of the medicament formulation can be delivered from the inhaler without large undeliverable volumes remaining below the level of the valve inlet.
  • O-ring 12B and gasket seal 92 seal the valve ferrule 2B onto the vial IB, each providing a back-up seal for the other element.
  • An annular member 90B projects from a position near the wall IB of the container toward the central axis and prevents direct communication of unduly high concentrations of medicament in a position near the wall of the container to the valve inlet
  • the annular region 84B collects the unduly high concentrations of medicament or sediment in a manner that restricts its access to the valve inlet 4B.
  • the unduly high medicament concentration must travel upward in Figure 2 from region 84B, then downward through the opening 82B and into valve inlet region 4B. After travelling such a labyrinth like path, the unduly high medicament concentration would have had ample opportunity to mix with the rest of the formulation to thereby eliminate the excessive medicament concentration.
  • the opening 82B is sized and shaped to afford access for the formulation to the valve inlet 4B.
  • the opening 82B can be circular with a diameter between about 2 millimeters and about 6 millimeters, and preferably between about 4 millimeters and about 4.5 millimeters.
  • the opening should have a sufficient diameter, or otherwise must be appropriately positioned or shaped, to ensure that the shoulder region 3B of the bottle emptier 3 cannot collide with annular member 90B as the bottle emptier moves along the central axis of the inhaler during valve actuation.
  • FIG 3 illustrates a third alternative embodiment of a device according to the present invention which has many parts that are essentially the same as the parts of the device shown in Figure 1 and which have been identified by the same reference number to which the suffix "C" has been added.
  • the metered dose inhaler comprises a metering valve 91 , and a ferrule 2C crimped onto the neck of vial IC which contains the medicament formulation.
  • O-ring 12C provides a gas-tight seal between vial IC and ferrule 2C.
  • the metering valve 91 comprises a body 52 having an annular seal or gasket 56.
  • the body 52 defines a chamber 6 having an inlet passage 4C and an outlet passage 10 for dispensing pressurised aerosol formulation.
  • a valve stem 54 extends through the chamber 6 and is movable between a closed or priming position shown in figure 3 and a dispensing position (not shown).
  • the valve stem 54 is biased to its dispensing position by means of a spring 59.
  • the valve stem 54 is fitted with an inner seal 16 and an outer seal 18 which provide gas-tight seals between the valve stem 54 and the inner wall of the chamber 6.
  • the chamber 6, the external dimensions of the valve stem 54, and the position of the seals 16, 18 are arranged to define a pre- determined volume within the chamber 6 between the seals 16,18.
  • valve stem 54 In operation the valve stem 54 is moved inwardly against the bias of the spring 59 to the priming position shown in Figure 3. In the closed or priming position, aerosol formulation contained in vial 1 C may enter or leave the chamber via the annular inlet between the seal 16 and the open end of the chamber. Access to the valve inlet in this design is somewhat free, thereby enhancing the value of the annular member 90C in this design.
  • the valve stem 54 When the valve stem 54 is released, the valve stem moves to its dispensing position (not shown) under the influence of the spring 59. During this movement, the valve seal 16 enters the chamber 6 thereby trapping a metered volume of aerosol formulation between the seals 16, 18 and the walls of the chamber. Further movement of the valve stem 54 moves the metered volume of formulation along the chamber until the valve seal
  • the outlet passage 10 passes the outlet passage 10 thereby allowing the outlet passage 10 to communicate directly with the metered volume of formulation.
  • the formulation is self-propelling and is sprayed through the outlet passage 10 under the influence of the vaporising aerosol propellant.
  • the outlet passage 10 may incorporate one or more small orifices, as shown, to aid break-up of the spray without the need for a separate actuator orifice.
  • Annular member 90C projects from a position near the wall IC of the container toward the central axis and prevents direct communication of unduly high concentrations of medicament in a position near the wall of the container to the valve inlet 4C.
  • the annular region 84C collects the unduly high concentrations of medicament or sediment in a manner that the presence of annular member 90C restricts its direct access to the valve inlet 4C.
  • the unduly high medicament concentration must travel upward in Figure 3 from region 84C, then downward through the opening 82C and into 4C. After travelling such a labyrinth like path, the unduly high medicament concentration would have had ample opportunity to mix with the rest of the formulation to thereby eliminate the excessive medicament concentration.
  • the opening 82C is sized and shaped to afford access for the formulation to the valve inlet 4C.
  • the opening 82C can be circular with a diameter between about 2 millimeters and about 6 millimeters, and preferably between about 4 millimeters and about 4.5 millimeters.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Nozzles (AREA)

Abstract

L'invention concerne un appareil utilisé avec un récipient (15) pour aérosol sous pression possédant une paroi cylindrique (1A) avec un axe central. La paroi délimite la partie principale de stockage du récipient pour aérosol ainsi qu'un orifice. L'appareil comprend une ferrure (2A) destinée à obturer l'orifice et une vanne doseuse (62) servant à distribuer des doses d'une préparation en aérosol contenue dans le récipient. La vanne, qui possède une entrée (4A), est disposée de préférence dans la ferrure, sensiblement le long de l'axe central. L'appareil possède également un élément annulaire (90A) muni d'une extrémité interne qui permet la communication fluidique entre la partie principale de stockage du récipient pour aérosol et l'entrée de la vanne. On choisit la forme, la taille et la position de l'élément annulaire de manière à limiter la communication fluidique entre la partie principale de stockage du récipient et l'entrée de la vanne à la communication fluidique s'effectuant à travers l'orifice (82A) de l'élément annulaire, ledit orifice étant disposé près de l'axe central.
PCT/US1999/001004 1998-01-20 1999-01-19 Distributeur d'aerosol WO1999036334A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99904119A EP1049637A1 (fr) 1998-01-20 1999-01-19 Distributeur d'aerosol
AU24588/99A AU2458899A (en) 1998-01-20 1999-01-19 Aerosol dispenser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9801185.1A GB9801185D0 (en) 1998-01-20 1998-01-20 Dispenser
GB9801185.1 1998-01-20

Publications (1)

Publication Number Publication Date
WO1999036334A1 true WO1999036334A1 (fr) 1999-07-22

Family

ID=10825584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001004 WO1999036334A1 (fr) 1998-01-20 1999-01-19 Distributeur d'aerosol

Country Status (4)

Country Link
EP (1) EP1049637A1 (fr)
AU (1) AU2458899A (fr)
GB (1) GB9801185D0 (fr)
WO (1) WO1999036334A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041845A1 (fr) 1999-12-11 2001-06-14 Glaxo Group Limited Distributeur de medicaments
WO2001041846A1 (fr) 1999-12-11 2001-06-14 Glaxo Group Limited Distributeur de medicaments
WO2002030498A1 (fr) 2000-10-13 2002-04-18 Glaxo Group Limited Distributeur de medicaments
WO2003024623A1 (fr) 2001-09-21 2003-03-27 Glaxo Group Limited Elements constitutifs d'un distributeur de medicament
US6843392B1 (en) 1999-08-07 2005-01-18 Smith Kline Beecham Valve with a valve stem wiper
US7467629B2 (en) 2001-12-19 2008-12-23 Glaxo Group Limited Medicament dispenser with magneto-rheological fluid actuator

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2178398A (en) 1985-07-17 1987-02-11 Bespak Plc Metering valve for pressurised dispensing containers
GB2198117A (en) 1986-11-28 1988-06-08 Glaxo Group Ltd Aerosol metering valve assembly
US4944433A (en) 1988-01-28 1990-07-31 Boehringer Ingelheim Kg Sediment baffle for valves of pressurized containers
GB2298187A (en) 1995-02-24 1996-08-28 Bespak Plc Metering valve
WO1996028367A2 (fr) 1995-03-10 1996-09-19 Minnesota Mining And Manufacturing Company Soupapes pour bombes aerosol
EP0801009A1 (fr) * 1996-04-09 1997-10-15 Bespak plc Soupape de dosage pour dispenseurs
US5775321A (en) * 1993-04-30 1998-07-07 Minnesota Mining And Manufacturing Company Seal configuration for aerosol canister

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2178398A (en) 1985-07-17 1987-02-11 Bespak Plc Metering valve for pressurised dispensing containers
GB2198117A (en) 1986-11-28 1988-06-08 Glaxo Group Ltd Aerosol metering valve assembly
US4944433A (en) 1988-01-28 1990-07-31 Boehringer Ingelheim Kg Sediment baffle for valves of pressurized containers
US5775321A (en) * 1993-04-30 1998-07-07 Minnesota Mining And Manufacturing Company Seal configuration for aerosol canister
GB2298187A (en) 1995-02-24 1996-08-28 Bespak Plc Metering valve
WO1996028367A2 (fr) 1995-03-10 1996-09-19 Minnesota Mining And Manufacturing Company Soupapes pour bombes aerosol
EP0870699A2 (fr) * 1995-03-10 1998-10-14 Minnesota Mining And Manufacturing Company Valve pour bombes aérosol
EP0801009A1 (fr) * 1996-04-09 1997-10-15 Bespak plc Soupape de dosage pour dispenseurs

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6843392B1 (en) 1999-08-07 2005-01-18 Smith Kline Beecham Valve with a valve stem wiper
WO2001041845A1 (fr) 1999-12-11 2001-06-14 Glaxo Group Limited Distributeur de medicaments
WO2001041849A2 (fr) 1999-12-11 2001-06-14 Glaxo Group Limited Distributeur de medicaments
WO2001041846A1 (fr) 1999-12-11 2001-06-14 Glaxo Group Limited Distributeur de medicaments
US6981499B2 (en) 1999-12-11 2006-01-03 Glaxo Group Limited Medicament dispenser
US7322355B2 (en) 1999-12-11 2008-01-29 Smith Kline Beecham Corporation Medicament dispenser
WO2002030498A1 (fr) 2000-10-13 2002-04-18 Glaxo Group Limited Distributeur de medicaments
WO2003024623A1 (fr) 2001-09-21 2003-03-27 Glaxo Group Limited Elements constitutifs d'un distributeur de medicament
US7467629B2 (en) 2001-12-19 2008-12-23 Glaxo Group Limited Medicament dispenser with magneto-rheological fluid actuator

Also Published As

Publication number Publication date
GB9801185D0 (en) 1998-03-18
EP1049637A1 (fr) 2000-11-08
AU2458899A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
US5477992A (en) Metered-dose aerosol valves
AP988A (en) Valve for Aerosol container.
US9096371B2 (en) Metering valve and dispensing apparatus
EP0260067B1 (fr) Appareil pour la décharge d'une quantité prédéterminée d'un fluide sous pression
EA002036B1 (ru) Клапан аэрозольного контейнера
EP0801009B1 (fr) Soupape de dosage pour dispenseurs
US20070007308A1 (en) Metering valve
US7959042B2 (en) In metering valves for pressurised dispensing containers
EP1049637A1 (fr) Distributeur d'aerosol
US20080224082A1 (en) Valves
GB2470403A (en) Valve assembly with valve stem for use with an aerosol canister
GB2401099A (en) Improvements in valves for pressurised dispensing containers
GB2439402A (en) Methods of sterilisation of aerosol valve components
HK1065754B (en) Ring for an aerosol valve
HK1021526B (en) Valve for aerosol container
GB2464943A (en) A valve stem for a metering valve
MXPA99005964A (en) Valve for aerosol container

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999904119

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999904119

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999904119

Country of ref document: EP